Working Document, September 2017
Department of AIDS Control
Ministry of Health & Family Welfare
Migration & health position paper series
Cross-cutting health themes
Tuberculosis, Migration and human mobility
First WHO Global Ministerial Conference
Ending TB in the Sustainable Development Era: A Multisectoral Response
Moscow, Russian Federation, 16-17 November 2017
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
From choice, a world of possibilities
Техническая записка;
Целью настоящей Технической записки является оказание содействия кандидатам наполучение грантов Глобального фонда при рассмотрении ...возможностей включения программ, направленных на устранение барьеров, обусловленных нарушением прав человека и гендерным неравенством, которые препятствуют получению услуг по профилактике, диагностике и лечению туберкулеза (ТБ), в запросы на финансирование, а также оказание помощивсем заинтересованным сторонам в том, чтобы программы по борьбе с ТБ обеспечивали продвижение и защиту прав человека и гендерного равенства.
more
Resources for the Prevention and Treatment of Substance Use Disorders (SUD)
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more